Cutaneous vasculitis associated with molecular tergeted therapies: systematic review of the literature.
Adverse drug events
Cutaneous leukocytoclastic vasculitides
Drug safety
Etiology
Molecular targeted therapies
Vasculitis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
19
06
2022
accepted:
05
10
2022
revised:
04
10
2022
pubmed:
13
11
2022
medline:
27
1
2023
entrez:
12
11
2022
Statut:
ppublish
Résumé
Cutaneo us vasculitis (CV) has a broad spectrum of etiologies, and drugs are one of the main culprits. With the increasing use of targeted therapies in medicine, especially in rheumatology and oncology, the number of CV cases reported due to these drugs has increased. Therefore, the recognition and treatment of CV associated with targeted agents have become more and more important. In the literature, anti-TNFs (n = 73, 59.5%), secukinumab (n = 7, 6%), rituximab (n = 5, 4%), tocilizumab (n = 1, 0.8%), ustekinumab (n = 8, 6.5%), abatacept (n = 3, 2.4%), Janus kinase inhibitors (n = 3, 2.4%), alemtuzumab (n = 3, 2.4%), and immune checkpoint inhibitors (n = 20, 16%) have been reported as responsible agents. However, our knowledge of the pathogenetic mechanisms is fairly limited, and the standardized management is yet to be established. Furthermore, though it is uncommon, this complication may pose a safety issue. In this manuscript, we reviewed the literature on CV with or without systemic involvement related to targeted agents. We also proposed the pathogenetic mechanisms of these adverse events. Thus, we aimed to make it easier for clinicians to manage similar cases by reviewing the diagnosis and treatment processes.
Identifiants
pubmed: 36369405
doi: 10.1007/s10067-022-06406-6
pii: 10.1007/s10067-022-06406-6
doi:
Substances chimiques
Abatacept
7D0YB67S97
Antineoplastic Agents
0
Rituximab
4F4X42SYQ6
Ustekinumab
FU77B4U5Z0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
339-357Informations de copyright
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Daxini A, Cronin K, Sreih AG (2018) Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol 37(9):2579–2584
doi: 10.1007/s10067-018-4177-0
Carlson JA (2010) The histological assessment of cutaneous vasculitis. Histopathology 56(1):3–23
doi: 10.1111/j.1365-2559.2009.03443.x
Fraticelli P, Benfaremo D, Gabrielli A (2021) Diagnosis and management of leukocytoclastic vasculitis. Intern Emerg Med 16:831–841
doi: 10.1007/s11739-021-02688-x
Stewart LA, Clarke M, Rovers M et al (2015) Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement. JAMA 313:1657–1665
doi: 10.1001/jama.2015.3656
Chelli C, Loget J, Vanhaecke C et al (2020) Cutaneous vasculitis with gut ınvolvement during secukinumab treatment for psoriatic arthritis. Acta Derm Venereol 100:adv00077
doi: 10.2340/00015555-3435
Martinez-Taboada VM, Val-Bernal JF, Pesquera LC et al (2006) Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol 35:322–323
doi: 10.1080/03009740600557249
McCain ME, Quinet RJ, Davis WE (2002) Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) 41:116–117
doi: 10.1093/rheumatology/41.1.116
McIlwain L, Carter JD, Bin-Sagheer S, Vasey FB, Nord J (2003) Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 36:411–413
doi: 10.1097/00004836-200305000-00010
Orpin SD, Majmudar VB, Soon C, Azam NA, Salim A (2006) Adalimumab causing vasculitis. Br J Dermatol 154:998–999
doi: 10.1111/j.1365-2133.2006.07195.x
Roux CH, Brocq O, Albert C, Breuil V, Euller-Ziegler L (2004) Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine 71:444–445
doi: 10.1016/j.jbspin.2004.05.008
Wendling D, Streit G, Lehuede G, Toussirot E, Aubin A, Petitjean A (2006) Cutaneous lymphocytic vasculitis during TNFalpha antagonist therapy for polyarthritis. Joint Bone Spine 73:215–216
doi: 10.1016/j.jbspin.2005.04.004
Giorgio V, Blasi E, Rigante D et al (2021) Anti-TNF-related leukocytoclastic vasculitis in ulcerative colitis: a case report. Int J Environ Res Public Health 18(13):6711
doi: 10.3390/ijerph18136711
Rahman FZ, Takhar GK, Roy O, Shepherd A, Bloom SL, McCartney SA (2010) Henoch-Schönlein purpura complicating adalimumab therapy for Crohn’s disease. World J Gastrointest Pharmacol Ther 1(5):119–122
doi: 10.4292/wjgpt.v1.i5.119
Sehgal R, Stratman EJ, Cutlan JE (2018) Biologic agent-associated cutaneous adverse events: a single center experience. Clin Med Res 16(1–2):41–46
doi: 10.3121/cmr.2017.1364
Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM (2003) Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 206(4):388–390
doi: 10.1159/000069965
Pontikaki I, Shahi E, Frasin LA et al (2012) Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol 42(2):131–134
doi: 10.1007/s12016-011-8262-2
Numakura T, Tamada T, Nara M, Muramatsu S, Murakami K, Kikuchi T, Kobayashi M, Muroi M, Okazaki T, Takagi S, Eishi Y, Ichinose M (2016) Simultaneous development of sarcoidosis and cutaneous vasculitis in a patient with refractory Crohn’s disease during infliximab therapy. BMC Pulm Med 16:30
doi: 10.1186/s12890-016-0193-5
Juan A, Ribas B, Nadal C, Ros I (2005) Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept? J Rheumatol 32(10):2061 (author reply 2061-2)
Nakahigashi K, Egawa G, Miyachi Y, Kabashima K (2014) Digital vasculitis with eosinophilia possibly associated with etanercept therapy. Acta Derm Venereol 94(2):239–240
doi: 10.2340/00015555-1662
Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G (2006) Henoch-Schönlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol 12(5):249–251
doi: 10.1097/01.rhu.0000239901.34561.5e
Kishimoto K, Kawashima K, Fukunaga M et al (2021) ıntermittent purpura development associated with leukocytoclastic vasculitis ınduced by ınfliximab for Crohn’s disease. Intern Med 60(3):385–389
doi: 10.2169/internalmedicine.5340-20
Woody M, Warren D, Speck L, Jackson J (2017) Leukocytoclastic vasculitis drug reaction to certolizumab pegol. Proc (Bayl Univ Med Cent) 30(2):213–214
Amarante CF, Acedo LM, Rabay FM et al (2015) Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab. An Bras Dermatol 90(3 Suppl 1):121–124
doi: 10.1590/abd1806-4841.20153834
Rolle AS, Zimmermann B, Poon SH (2013) Etanercept-induced Henoch-Schönlein purpura in a patient with ankylosing spondylitis. J Clin Rheumatol 19(2):90–93
doi: 10.1097/RHU.0b013e3182863027
Asahina A, Ohshima N, Nakayama H, Shirai A, Juji T, Matsui T (2010) Henoch-Schönlein purpura in a patient with rheumatoid arthritis receiving etanercept. Eur J Dermatol 20(4):521–522
doi: 10.1684/ejd.2010.0977
Pastore S, Londero M, Gortani G et al (2010) Infliximab-related vasculitis in patients affected by ulcerative colitis. J Pediatr Gastroenterol Nutr 51(2):226–228
doi: 10.1097/MPG.0b013e3181e5e198
Hemmati I, Kur J (2013) Adalimumab-associated antiphospholipid syndrome: a case report and review of the literature. Clin Rheumatol 32(7):1095–1098
doi: 10.1007/s10067-013-2244-0
Fadahunsi AW, Garcia-Rosell M, Pattanaik D (2015) Hypocomplementemic Urticarial Vasculitis Syndrome Possibly Secondary to Etanercept Use. J Clin Rheumatol 21(5):274–275
doi: 10.1097/RHU.0000000000000269
Srivastava MD, Alexander F, Tuthill RJ (2005) Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol 61(4):329–36. https://doi.org/10.1111/j.1365-3083.2005.01570.x
Broshtilova V, Iliev E, Gantcheva M (2013) Etanercept-induced Wegener granulomatosis in a patient with rheumatoid arthritis. Dermatol Ther 26(1):73–76
doi: 10.1111/j.1529-8019.2012.01538.x
Jarrett SJ, Cunnane G, Conaghan PG et al (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30(10):2287–2291
Simms R, Kipgen D, Dahill S, Marshall D, Rodger RS (2008) ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. Am J Kidney Dis 51(3):e11–e14
doi: 10.1053/j.ajkd.2007.10.043
Hokama A, Sonosaki T, Zamami R, Aoyama H, Kinjo T, Fujita J (2019) Crohn disease complicated by IgA vasculitis during therapy with tumor necrosis factor-α inhibitor. Pol Arch Intern Med 129(4):283–284
Horai Y, Ishikawa H, Iwanaga N et al (2020) Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report. J Clin Pharm Ther 45(5):1179–1182
doi: 10.1111/jcpt.13117
Bostan E, Gulseren D, Yalici-Armagan B et al (2021) Vasculitis during certolizumab pegol and secukinumab treatment: report of two cases. Dermatol Ther 34(4):e15007
doi: 10.1111/dth.15007
Villani A, de Fata Salvatores G, Nappa P, Megna M, Fabbrocini G, Napolitano M (2019) Cutaneous leucocytoclastic vasculitis during secukinumab treatment. Ital J Dermatol Venerol 156(Suppl 1 to No 6):9–10
Reverte M, Etienne M, Fouchard M, Doucet L, Brenaut E, Misery L (2019) Occurrence of Henoch-Schönlein purpura in a patient treated with secukinumab. J Eur Acad Dermatol Venereol 33(12):e455–e457
doi: 10.1111/jdv.15776
da Silva Cendon Duran C, Barreto Santiago M. Cutaneous Vasculitis During Secukinumab Treatment. Eur J Case Rep Intern Med. 2020;7(10):001815. https://doi.org/10.12890/2020_001815
Calleja Algarra A, Aragón Miguel R, Andrés Lencina JJ et al (2021) Behçet’s-like disease during secukinumab treatment: new paradoxical reaction? J Dtsch Dermatol Ges Jan 19:116–118
Perkovic D, Simac P, Katic J (2021) IgA vasculitis during secukinumab therapy. Clin Rheumatol M 40:2071–2073
doi: 10.1007/s10067-020-05364-1
Dereure O, Navarro R, Rossi JF, Guilhou JJ (2001) Rituximab-induced vasculitis. Dermatology 203(1):83–84
doi: 10.1159/000051713
Kandula P, Kouides PA (2006) Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol 142:246–247
doi: 10.1001/archderm.142.2.246
Kim MJ, Kim HO, Kim HY, Park YM (2009) Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol 36(5):284–287
doi: 10.1111/j.1346-8138.2009.00639.x
Abe K, Itoh M, Asahina A (2019) Rituximab-induced vasculitis: does the immune complex of rituximab play a key role in developing paradoxical adverse events? J Dermatol 46(9):e311–e312
doi: 10.1111/1346-8138.14872
Kanchongkittiphon W, Monroy J (2020) Rituximab-induced Henoch-Schonlein purpura in a patient with mantle cell lymphoma. J Allergy Clin Immunol Pract 8(2):783-785.e1
doi: 10.1016/j.jaip.2019.07.041
Sakaue S, Sumitomo S, Kubo K, Fujio K, Yamamoto K (2014) Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology 53:1529–1530
doi: 10.1093/rheumatology/keu008
MacArthur KM, Merkel PA, Van Voorhees AS, Nguyen J, Rosenbach M (2016) Severe small-vessel vasculitis temporally associated with administration of ustekinumab. J Drugs Dermatol 15(3):359–362
Al Khalili A, Scott L, Dutz JP (2019) New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus. JAAD Case Rep 5(8):682–685
doi: 10.1016/j.jdcr.2019.05.022
Costa-Moreira P, Lopes S, Santos AL et al (2020) Leukocytoclastic vasculitis related to ustekinumab in a Crohn’s disease patient: first case report and literature review. J Crohns Colitis 14(2):274–276
doi: 10.1093/ecco-jcc/jjz128
Buck M, Dumic I, McDermott W et al (2020) Leukocytoclastic vasculitis as a rare dermatologic manifestation of Crohn’s disease mimicking cellulitis: a case report. BMC Gastroenterol 20(1):240
doi: 10.1186/s12876-020-01371-3
Chugh R, Proctor DD, Little A et al (2021) Cutaneous vasculitis after ustekinumab ınduction in Crohn’s disease. Inflamm Bowel Dis 27(3):e30–e31
doi: 10.1093/ibd/izaa285
Tomelleri A, Campochiaro C, De Luca G, Cavalli G, Dagna L (2018) Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: a case series. Eur J Intern Med 57:e11–e12
doi: 10.1016/j.ejim.2018.07.023
Kang A, Yuen M, Lee DJ (2018) Nivolumab-induced systemic vasculitis. JAAD case reports 4:606–608
doi: 10.1016/j.jdcr.2018.03.013
Franco F, Méndez M, Gutierrez L, Sanz J, Calvo V, Provencio M (2019) Nivolumab-associated digital small-vessel vasculitis in a patient with an advanced renal cell carcinoma. Immunotherapy 11(5):379–384
doi: 10.2217/imt-2018-0082
Nagaoka-Takatori A, Ishii M, Hayama K et al (2021) A case of IgA vasculitis during nivolumab therapy for renal cell carcinoma. Clin Cosmet Investig Dermatol 14:1885–1888
doi: 10.2147/CCID.S343876
Ho B, Larkin J, Heelan K (2021) Checkpoint ınhibitor-associated cutaneous small vessel vasculitis: a review of the literature. J Immunother 44(3):118–121
doi: 10.1097/CJI.0000000000000352
Asemota U, Gulati A, Kumar K, Janga K (2021) Nivolumab-ınduced crescentic ımmunoglobulin a nephropathy with Henoch-schonlein purpura features in a patient diagnosed with hepatocellular carcinoma. Cureus 13(10):e19110
Khaddour K, Singh V, Shayuk M (2019) Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review. BMC Cancer 19:449
doi: 10.1186/s12885-019-5661-x
Gallan AJ, Alexander E, Reid P, Kutuby F, Chang A, Henriksen KJ (2019) Renal vasculitis and pauci-immune glomerulonephritis associated with ımmune checkpoint ınhibitors. Am J Kidney Dis 74(6):853–856
doi: 10.1053/j.ajkd.2019.04.016
O’Connor P, Bhadbhade P, Khan Q, Williamson S (2020) Acral vascular syndrome during an immune checkpoint inhibitor. BMJ Case Rep 13(5):e233463
doi: 10.1136/bcr-2019-233463
Gambichler T, Strutzmann S, Tannapfel A, Susok L (2017) Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade. BMC Cancer 17:327
doi: 10.1186/s12885-017-3313-6
Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L (2018) Ipilimumab induced digital vasculitis. J Immunother Cancer 6:12
doi: 10.1186/s40425-018-0321-2
Castillo B, Gibbs J, Brohl AS, Seminario-Vidal L (2018) Checkpoint inhibitor-associated cutaneous small vessel vasculitis. JAAD case reports 4:675–677
doi: 10.1016/j.jdcr.2018.05.020
Belkaid S, Berger M, Nouvier M, Picard C, Dalle S (2020) A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma. Eur J Cancer 139:169–172
doi: 10.1016/j.ejca.2020.08.005
Panian J, Pan E, Shi V, Hinds B, Mckay RR (2022) Leukocytoclastic vasculitis ınduced by ımmune checkpoint ınhibition in a patient with advanced renal cell carcinoma. Oncology (Williston Park) 36(5):316–320
Comont T, Sibaud V, Mourey L, Cougoul P, Beyne-Rauzy O (2018) Immune checkpoint inhibitor-related acral vasculitis. J Immunother Cancer 6(1):120
doi: 10.1186/s40425-018-0443-6
Le Burel S, Champiat S, Routier E et al (2018) Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy. Ann Rheum Dis 77(3):468–470
doi: 10.1136/annrheumdis-2016-210820
Gupta S, Xu D, Hadfield J, Prentice D (2020) Durvalumab-associated vasculitis presenting as ‘the blue toe syndrome.’ BMJ Case Rep 13(11):e235886
doi: 10.1136/bcr-2020-235886
Garten L, Edwards K, Lezcano C et al (2017) Case report: Leukocytoclastic vasculitis in an MS patient following alemtuzumab treatment. Neurology 88:P5403
Sauer EM, Schliep S, Manger B et al (2018) Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 5(5):e488
doi: 10.1212/NXI.0000000000000488
Horisberger A, Pantazou V, Cuendet G, Ribi C, Dunet V, Théaudin M (2020) ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis. Mult Scler 26(12):1599–1602
doi: 10.1177/1352458519895449
Golmia A, Grinblat B, Finger E, Klieman C, Assir F, Scheinberg M (2008) The development of erythema elevatum diutinum in a patient with juvenile idiopathic arthritis under treatment with abatacept. Clin Rheumatol 27(1):105–106
doi: 10.1007/s10067-007-0743-6
Shibata S, Asano Y, Sato S (2013) Cutaneous polyarteritis nodosa localized to the arm receiving an infusion of abatacept. Eur J Dermatol 23(5):738–739
doi: 10.1684/ejd.2013.2160
Holt MH, Liu V, Fairley J (2018) Medium-vessel vasculitis presenting as multiple leg ulcers after treatment with abatacept. JAAD Case Rep 4(8):811–813
doi: 10.1016/j.jdcr.2018.06.021
Itoh I, Kasuno K, Yamamoto C et al (2020) IgA vasculitis developed as an adverse effect of tofacitinib taken for rheumatoid arthritis. Intern Med 59(6):817–821
doi: 10.2169/internalmedicine.3668-19
Turgutkaya A, Yavaşoğlu İ (2021) Ruxolitinib induced leukocytoclastic vasculitis. Med Clin (Barc) 157(10):501 (English Spanish)
doi: 10.1016/j.medcli.2020.11.014
Tığlıoğlu M, Tığlıoğlu P, Yıldız A (2022) Leukocytoclastic vasculitis due to ruxolitinib treatment: A rare adverse effect. J Clin Pharm Ther 47(4):544–547
doi: 10.1111/jcpt.13512
Chen KR, Carlson JA (2008) Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 9(2):71–92
doi: 10.2165/00128071-200809020-00001
da Silva Cendon Duran C, Souza da Paz A, Barreto Santiago M (2022) Vasculitis induced by biological agents used in rheumatology practice: a systematic review. Arch Rheumatol 37(2):300–310
doi: 10.46497/ArchRheumatol.2022.9049
Pérez-De-Lis M, Retamozo S, Flores-Chávez A et al (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf 16(11):1255–1271
doi: 10.1080/14740338.2017.1372421
Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22(5):847–861
doi: 10.1016/j.berh.2008.09.008
Sokumbi O, Wetter DA, Makol A, Warrington KJ (2012) Vasculitis associated with tumor Necrosis factor-α. Inhibitors Mayo Clin Proc 87:739–745
doi: 10.1016/j.mayocp.2012.04.011
Cambridge G, Wallace H, Bernstein RM, Leaker B (1994) Autoantibodies to myeloperoxidase in idiopathic and drug-induced systemic lupus erythematosus and vasculitis. Br J Rheumatol 33(2):109–114
doi: 10.1093/rheumatology/33.2.109
Ortiz-Sanjuán F, Blanco R, Hernández JL et al (2014) Drug-associated cutaneous vasculitis: study of 239 patients from a single referral center. J Rheumatol 41:2201–2207
doi: 10.3899/jrheum.140390
Nandeesh B, Tirumalae R (2013) Direct immunofluorescence in cutaneous vasculitis: experience from a referral hospital in India. Indian J Dermatol 58(1):22–25
doi: 10.4103/0019-5154.105280
Gower RG, Sams WM, Thorne EG et al (1977) Leukocytoclastic vasculitis: sequential appearance of immunoreactants and cellular changes in serial biopsies. J Invest Dermatol 69:477–484
doi: 10.1111/1523-1747.ep12511631
Claudy A (1998) Pathogenesis of leukocytoclastic vasculitis. Eur J Dermatol 8:75–79
Sais G, Vidaller A, Jucglá A et al (1997) Adhesion molecule expression and endothelial cell activation in cutaneous leukocytoclastic vasculitis. An immunohistologic and clinical study in 42 patients. Arch Dermatol 133:443–50
doi: 10.1001/archderm.1997.03890400041006
Jennette JC, Falk RJ, Hu P, Xiao H (2013) Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol 8:139–160
doi: 10.1146/annurev-pathol-011811-132453
González-Gay MA, García-Porrúa C (2002) Systemic vasculitides. Best Pract Res Clin Rheumatol 16(5):833–845
doi: 10.1053/berh.2002.0260